ReviewOpen forum infectious diseases2015
The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England.
Review in Open forum infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2018Trial
- Screening Strategies to Control Antibiotic-Resistant Bacteria: An Agent-Based Model.Antibiotics (Basel, Switzerland) · 2026Article
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Trends, Seasonality, and the Impact of COVID-19 on ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project-legacy and future.The Journal of antimicrobial chemotherapy · 2025Article
- Article
- The Role of Stakeholders' Understandings in Emerging Antimicrobial Resistance: A One Health Approach.Microorganisms · 2023Review
- Evaluation of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Epidemiology, clinical characteristics, and outcomes in the older patients in a tertiary teaching hospital in Malaysia.BMC infectious diseases · 2023Article
- Preventing healthcare-associated MRSA bacteremia: getting to the root of the problem.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Exploring the Barriers in the Uptake of the Dutch MRSA 'Search and Destroy' Policy Using the Cascade of Care Approach.Antibiotics (Basel, Switzerland) · 2022Article
- Hospital-Onset Bloodstream Infections Caused by Eight Sentinel Bacteria: A Nationwide Study in Israel, 2018-2019.Microorganisms · 2022Article
- Prevalence of methicillin-resistantPublic health action · 2021Article
- Probabilistic modelling of effects of antibiotics and calendar time on transmission of healthcare-associated infection.Scientific reports · 2021Article
- High Prevalence of Methicillin-ResistantTropical medicine and infectious disease · 2021Article
- The nadir that brought about national infection prevention and control policy.Journal of infection prevention · 2021Article
- Treatment of methicillin-resistantJAC-antimicrobial resistance · 2021Review
- Antimicrobial Resistance in ESKAPE Pathogens.Clinical microbiology reviews · 2020Review
- Things We Do For Good Reasons: Contact Precautions for Multidrug-resistant Organisms, Including MRSA and VRE.Journal of hospital medicine · 2019Article
- A strategy for tackling antimicrobial resistance: It's more than a prescribing problem.Journal of infection prevention · 2019Article
- Prospective genomic surveillance of methicillin-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) blood stream infection (BSI) is a major healthcare burden in some but not all healthcare settings, and it is associated with 10%-20% mortality. The introduction of mandatory reporting in England of MRSA BSI in 2001 was followed in 2004 by the setting of target reductions for all National Health Service hospitals. The original national target of a 50% reduction in MRSA BSI was considered by many experts to be unattainable, and yet this goal has been far exceeded (∼80% reduction with rates still declining). The transformation from endemic to sporadic MRSA BSI involved the implementation of serial national infection prevention directives, and the deployment of expert improvement teams in organizations failed to meet their improvement trajectory targets. We describe and appraise the components of the major public health infection prevention campaign that yielded major reductions in MRSA infection. There are important lessons and opportunities for other healthcare systems where MRSA infection remains endemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.